• Je něco špatně v tomto záznamu ?

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways

L. Minařík, K. Pimková, J. Kokavec, A. Schaffartziková, F. Vellieux, V. Kulvait, L. Daumová, N. Dusilková, A. Jonášová, KS. Vargová, P. Králová Viziová, R. Sedláček, Z. Zemanová, T. Stopka

. 2022 ; 11 (2) : . [pub] 20220111

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011346

Grantová podpora
19-03586S Czech Science Foundation
NV19-08-00144, NU21-08-00312, CZ-DRO-VFN64165 Ministry of Health
GAUK 1672119, SVV260521, UNCE/MED/016, ProgresQ26 Charles University

The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive research. A better understanding of mechanisms by which the MDS cell becomes to tolerate HMA and progresses to acute myeloid leukemia (AML) requires the development of new cellular models. From MDS/AML cell lines we developed a model of 5-azacytidine (AZA) resistance whose stability was validated by a transplantation approach into immunocompromised mice. When investigating mRNA expression and DNA variants of the AZA resistant phenotype we observed deregulation of several cancer-related pathways including the phosphatidylinosito-3 kinase signaling. We have further shown that these pathways can be modulated by specific inhibitors that, while blocking the proliferation of AZA resistant cells, are unable to increase their sensitivity to AZA. Our data reveal a set of molecular mechanisms that can be targeted to expand therapeutic options during progression on AZA therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011346
003      
CZ-PrNML
005      
20220506131446.0
007      
ta
008      
220425s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cells11020223 $2 doi
035    __
$a (PubMed)35053339
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Minařík, Lubomír $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic $u Clinic Haematology, General Faculty Hospital, 12808 Prague, Czech Republic
245    10
$a Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways / $c L. Minařík, K. Pimková, J. Kokavec, A. Schaffartziková, F. Vellieux, V. Kulvait, L. Daumová, N. Dusilková, A. Jonášová, KS. Vargová, P. Králová Viziová, R. Sedláček, Z. Zemanová, T. Stopka
520    9_
$a The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive research. A better understanding of mechanisms by which the MDS cell becomes to tolerate HMA and progresses to acute myeloid leukemia (AML) requires the development of new cellular models. From MDS/AML cell lines we developed a model of 5-azacytidine (AZA) resistance whose stability was validated by a transplantation approach into immunocompromised mice. When investigating mRNA expression and DNA variants of the AZA resistant phenotype we observed deregulation of several cancer-related pathways including the phosphatidylinosito-3 kinase signaling. We have further shown that these pathways can be modulated by specific inhibitors that, while blocking the proliferation of AZA resistant cells, are unable to increase their sensitivity to AZA. Our data reveal a set of molecular mechanisms that can be targeted to expand therapeutic options during progression on AZA therapy.
650    _2
$a zvířata $7 D000818
650    _2
$a azacytidin $x farmakologie $7 D001374
650    _2
$a DNA nádorová $x genetika $7 D004273
650    12
$a chemorezistence $x účinky léků $x genetika $7 D019008
650    _2
$a myši $7 D051379
650    _2
$a myši SCID $7 D016513
650    12
$a biologické modely $7 D008954
650    _2
$a anotace sekvence $7 D058977
650    _2
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
650    _2
$a protoonkogenní proteiny c-akt $x metabolismus $7 D051057
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a transkriptom $x genetika $7 D059467
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pimková, Kristýna $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic
700    1_
$a Kokavec, Juraj $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic
700    1_
$a Schaffartziková, Adéla $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic
700    1_
$a Vellieux, Fréderic $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic $1 https://orcid.org/0000000219225707
700    1_
$a Kulvait, Vojtěch $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic
700    1_
$a Daumová, Lenka $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic
700    1_
$a Dusilková, Nina $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic $u Clinic Haematology, General Faculty Hospital, 12808 Prague, Czech Republic $u Pathophysiology, 1st Medical Faculty, Charles University, 12853 Prague, Czech Republic
700    1_
$a Jonášová, Anna $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic
700    1_
$a Vargová, Karina Savvulidi $u Pathophysiology, 1st Medical Faculty, Charles University, 12853 Prague, Czech Republic $1 https://orcid.org/0000000249694133
700    1_
$a Králová Viziová, Petra $u Czech Centre for Phenogenomics, Institute of Molecular Genetics, 25250 Vestec, Czech Republic $1 https://orcid.org/0000000293855504
700    1_
$a Sedláček, Radislav $u Czech Centre for Phenogenomics, Institute of Molecular Genetics, 25250 Vestec, Czech Republic
700    1_
$a Zemanová, Zuzana $u Cytogenetics, General Faculty Hospital, 12808 Prague, Czech Republic $1 https://orcid.org/0000000275386601 $7 nlk20050170627
700    1_
$a Stopka, Tomáš $u BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic $u Clinic Haematology, General Faculty Hospital, 12808 Prague, Czech Republic $1 https://orcid.org/0000000172366894 $7 xx0101300
773    0_
$w MED00194911 $t Cells $x 2073-4409 $g Roč. 11, č. 2 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35053339 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131438 $b ABA008
999    __
$a ok $b bmc $g 1789100 $s 1162544
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 11 $c 2 $e 20220111 $i 2073-4409 $m Cells $n Cells $x MED00194911
GRA    __
$a 19-03586S $p Czech Science Foundation
GRA    __
$a NV19-08-00144, NU21-08-00312, CZ-DRO-VFN64165 $p Ministry of Health
GRA    __
$a GAUK 1672119, SVV260521, UNCE/MED/016, ProgresQ26 $p Charles University
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace